Skip to main content
SpringerLink
Log in
Book cover

Progress in Anti-Cancer Chemotherapy pp 131–174Cite as

New Drug Combinations in NSCLC: Progress in Cancer Therapy

  • Conference paper

  • 61 Accesses

Part of the book series: Progress in Anti-Cancer Chemotherapy ((ANTI-CANCER,volume 3))

Abstract

Lung cancer is the leading cause of cancer mortality in both men and women in the United States, accounting for 29% of all cancer deaths in 1997. The estimated number of new cases of lung cancer in 1997 was 178,000 with an estimated 160,400 lung cancer deaths [1]. Lung cancer is the third most common cancer in the United States behind prostate and breast cancer, but more Americans will die from this dreaded disease than from breast cancer, prostate cancer and colorectal cancer combined because of the low 14% cure rate [1]. This low cure rate can be ascribed almost exclusively to the high propensity for metastatic spread, the lack of effective screening measures and the inability of systemic therapy to cure metastatic spread.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Parker SL, Tong T, Bolden S, Wingo PA (1997) Cancer Statistics. Cancer J Clin 47: 5–27

    Article  CAS  Google Scholar 

  2. Mountain CF (1997) Revisions in the international system for staging lung cancer. Chest 111:1710–1717

    Article  PubMed  CAS  Google Scholar 

  3. Non-small Cell Collaborative Group (1995) Chemotherapy in non-small cell lung cancer. Meta-analysis using updated data in individual patients from 52 randomized clinical trials. Brit Med J 311:899–909

    Article  Google Scholar 

  4. Bunn PA Jr (1989) The expanding role of cisplatin in the treatment of non-small cell lung cancer. Semin Oncol 16(Suppl 6): 10–21

    PubMed  Google Scholar 

  5. Billingham LJ, Cullen MH, Woods J et al (1997) Mitomycin, ifosfamide and cisplatin in non-small cell lung cancer. Results of a randomized trial evaluating palliation and quality of life. Lung Cancer 18(Suppl 1):A9

    Article  Google Scholar 

  6. Ellis PA, Smith IE, Hardy JR et al (1995) Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small cell lung cancer. Brit J Cancer 71:366–370

    Article  PubMed  CAS  Google Scholar 

  7. Bunn PA Jr, Kelly K (1998) New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer. Review of the literature and future directions. Clin Cancer Res 5:1087–1100

    Google Scholar 

  8. Vokes EE (1995) Integration of Vinorelbine into Chemotherapy Strategies for Non-Small Cell Lung Cancer. Oncology 9:565–575

    PubMed  CAS  Google Scholar 

  9. LeChevalier T, Pujol JL, Douillard JY et al (1994) A three arm trial of vinorelbine (Navelbine) plus cisplatin, vindesine plus cisplatin, and single agent vinorelbine in the treatment of non-small cell lung cancer: An expanded analysis. Semin Oncol 21:28–33

    CAS  Google Scholar 

  10. Crawford J, O’Rourke M, Schiller J et al (1996) Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small cell lung cancer. J Clin Oncol 14:2777–2784

    Google Scholar 

  11. Pronzato P, Landucci M, Vaira F et al (1994) Failure of vinorelbine to produce responses in pretreated non-small cell lung cancer patients. Anticancer Res 14:1413–1416

    PubMed  CAS  Google Scholar 

  12. Rinaldi M, Delia Giuha M, Venturo I et al (1994) Vinorelbine as single agent in the treatment of advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 13: A360

    Google Scholar 

  13. Santoro A, Maiorino L, Santoro M (1994) Second line with vinorelbine in the weekly monotherapy for the treatment of advanced non-small cell lung cancer. Lung Cancer 11(Suppl 1):A130

    Article  Google Scholar 

  14. Tononi A, Panzini I, Oliverio G et al (1997) Vinorelbine chemotherapy in non-small cell lung cancer: experience in elderly patients. J Chemother 9(4):304–308

    PubMed  CAS  Google Scholar 

  15. Gridelli C, Perrone F, Gallo C et al: Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer. A two-stage phase II study. E J Cancer 33: 392–397, 1997

    Article  CAS  Google Scholar 

  16. Veronesi A, Crivellari D, Magri MD et al (1996) Vinorelbine treatment of advanced non small cell lung cancer with special emphasis on elderly patients. Eur J Cancer 32A: 1809–1811

    Article  PubMed  CAS  Google Scholar 

  17. Furuse K, Fukuoka M, Hara N et al (1998) Vinorelbine in the Treatment of Elderly patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 17:A1862

    Google Scholar 

  18. Perrone F, Rossi A, Ianniello GP et al (1998) Vinorelbine plus best supportive care (BSC) vs BSC in the treatment of advanced non-small cell lung cancer elderly patients. Results of a phase III randomized trial. Proc Am Soc Clin Oncol 17: A1752

    Google Scholar 

  19. Chang AY, Kubota K, Kawahara M et al (1993) A phase II study of Taxol, merbarone and piroxantrone in stage IV non-small cell lung cancer: the Eastern Cooperative Oncology Group results. J Natl Cancer Inst 85:388–394

    Article  PubMed  CAS  Google Scholar 

  20. Murphy WK, Fosella F, Winn et al (1993) Phase II study of Taxol in patients with untreated advanced non-small cell lung cancer. J Natl Cancer Inst 85:384–387

    Article  PubMed  CAS  Google Scholar 

  21. Gatzemeier U, Heckmayr M, Neuhauss R et al (1995) Phase II study of paclitaxel for the treatment of advanced inoperable non-small cell lung cancer. Lung Cancer 12(Suppl 2): 101–106

    Article  Google Scholar 

  22. Hainsworth JD, Hopkins L, Thomas M et al (1994) Taxol administered by one hour infusion: Preliminary results of a phase I/II study comparing two dose schedules. Lung Cancer 11(Suppl 11):A96

    Google Scholar 

  23. Akerley W, Choy H, Safran H et al (1997) Weekly paclitaxel in patients with advanced lung cancer: preliminary data from a phase II trial. Semin Oncol 24(Suppl 12):10–13

    CAS  Google Scholar 

  24. Chang A, Boros L, Asbury R et al (1998) Weekly moderate-dose paclitaxel in stage IV non-small cell lung cancer. Proc Am Soc Clin Oncol 17:A1806

    Google Scholar 

  25. Murphy WK, Fosella FV, Winn RJ et al (1994) Phase II study of Taxol in patients with non-small cell lung cancer who have failed platinum containing chemotherapy. Proc Am Soc Clin Oncol 13:A363

    Google Scholar 

  26. Ruckdeschel J, Wagner H, Williams C et al (1994) Second line chemotherapy for resistant metastatic non-small cell lung cancer: The role of Taxol. Proc Am Soc Clin Oncol 13:A357

    Google Scholar 

  27. Hainsworth JD, Thompson DS, Greco FA (1995) Paclitaxel by 1 hr infusion: An active drug in metastatic non-small cell lung cancer. J Clin Oncol 13:1609–1614

    PubMed  CAS  Google Scholar 

  28. LeChevalier T, Mattson K, Bosquee L et al (1997) Phase II study of docetaxel (Tax- otere) in locally advanced or metastatic non-small cell lung cancer (NSCLC); Interim report on 204 patients. Lung Cancer 18(Suppl 1):A83

    Google Scholar 

  29. Fossella FV, Lee JS, Hong WK (1997) Management strategies for recurrent non- small cell lung cancer. Semin Oncol 24:455–462

    PubMed  CAS  Google Scholar 

  30. Gandara DR, Vokes E, Green M et al (1997) Docetaxel (Taxotere) in platinum-treated non-small cell lung cancer (NSCLC): confirmation of prolonged survival in a multi- center trial. Proc Am Soc Clin Oncol, 16:A1632

    Google Scholar 

  31. Fossella F, Devore R, Kerr R et al (1998) Randomised phase III study of Taxotere (100 mg/m2 and 75 mg/m2) versus Vinorelbine or Ifosfamide in non-small cell lung cancer patients, previously treated with platinum-based chemotherapy. Proc Am Soc Clin Oncol 17:A1859

    Google Scholar 

  32. Manegold C: Single agent gemcitabine versus cistaplin/etoposide with inoperable, locally advanced, or metastatic non-small cell lung cancer. Semin Oncol 25 (suppl 9): l=-22, 1998

    Google Scholar 

  33. Pemg RP, Chen YM, Ming-Liu J et al (1997) Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small cell lung cancer in a phase II randomized study. J Clin Oncol 15:2097–2102

    Google Scholar 

  34. Crino L, Mosconi AM, Scagliotti GV et al: Gemcitabine as second-line treatment for relapsing or refractory advanced non-small cell lung cancer: a phase II trial. Semin Oncol 25 (suppl 9): 23–26, 1998

    PubMed  CAS  Google Scholar 

  35. Rosvold R, Langer CJ, Schilder R et al (1998) Salvage therapy with gemcitabine in advanced non-small cell lung cancer progressing after prior carboplatin-paclitaxel. Proc Am Soc Clin Oncol 17:A1797

    Google Scholar 

  36. Martin C, Artizzoni A and Rosso R: Gemcitabine: safety profile and efficacy in non- small cell lung cancer unaffected by age. Aging 9: 297–303, 1997

    PubMed  CAS  Google Scholar 

  37. CPT-11 Cooperative Group Study (1991) A phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer. Jpn J Cancer Chemother 18:1013–1019

    Google Scholar 

  38. Nakai H, Fukuoka M, Furuse K et al (1991) An early phase II study of CPT-11 for primary lung cancer. Jpn J Cancer Chemother 18:607–612

    CAS  Google Scholar 

  39. Niitani H, Fukuoka M, Nagao K (1994) Clinical development of irinotecan (CPT-11) in lung cancers. Lung Cancer 11 (Suppl 2):30–31

    Google Scholar 

  40. Wozniak AJ, Crowley JJ, Balcerzak SP et al: Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small cell lung cancer: A Southwest Oncology Group Study. J Clin Oncol 16: 2459–2465, 1998

    PubMed  CAS  Google Scholar 

  41. Bonomi P, Kim K, Kugler K et al (1997) Results of a Phase III Trial comparing taxol- cisplatin (TC) regimens to etoposide-cisplatin (EC) in non-small cell lung cancer (NSCLC) Lung Cancer 18(Suppl 1):A28

    Google Scholar 

  42. Bunn PA (1989) Review of therapeutic trials of carboplatin in lung cancer. Semin Oncol 16:27–33

    PubMed  Google Scholar 

  43. Garst, J, Crawford J, O’Rourke M et al (1996) Vinorelbine (NVB) and carboplatin for the treatment of patients with advanced non-small cell lung cancer (NSCLC): a phase II response, toxicity and survival study. Proc Am Soc Clin Oncol 15:A1233

    Google Scholar 

  44. Masotti A, Borzellino G, Zannini G et al (1995) Efficacy and toxicity of vinorelbine- carboplatin combinations in the treatment of advanced adenocarcinoma or large cell carcinoma of the lung. Tumori 81:112–116

    PubMed  CAS  Google Scholar 

  45. Pronzato P, Ghio E, Losardo PL et al (1996) Carboplatin and vinorelbine in advanced non-small cell lung cancer. Cancer Chemother Pharmacol 37:610–612

    Article  PubMed  CAS  Google Scholar 

  46. Pennucci MC, Baldini E, Portalone L et al (1996) Cisplatin, vindesine, mitomycin vs. cisplatin, ifosfamide, navelbine vs. carboplatin, navelbine for stage IIIB/IV non- small cell lung cancer patients: a randomized phase II FONICAP trial. Proc Am Soc Clin Oncol 14:A1107

    Google Scholar 

  47. Giaccone P, Splinter TA, Debruyne C et al (1998) Randomized study of palitaxel-cis- platin versus cisplatin-teniposide in patients with advanced non-small cell lung cancer. J Clin Oncol 16(6):2133–2141

    PubMed  CAS  Google Scholar 

  48. Gatzemeier U, von Pawel J, Gottfried M et al (1998) Phase II comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 17:A1748

    Google Scholar 

  49. Langer CJ, Millenson M, Rosvold E et al (1997) Paclitaxel (1 hour) and carboplatin (AUC 7.5) in advanced non-small cell lung cancer: A phase II study of the Fox Chase Cancer Center and Its Network. Semin Oncol 24(Suppl 12):81–88

    CAS  Google Scholar 

  50. Greco FA, Hainsworth JD (1998) One hour paclitaxel plus carboplatin in advanced non-small cell lung cancer: Preliminary results of a Multicenter study. Oncology 12(Suppl 2):71–73

    PubMed  CAS  Google Scholar 

  51. Belani CP, Natale RB, Lee JS et al (1998) Randomized phase III trial comparing cis- platin/etoposide versus carboplatin/paclitaxel in advanced and metastatic non-small cell lung cancer. Proc Am Soc Clin Oncol 17:A1751

    Google Scholar 

  52. Ukena D, Leutz M, Schroder R et al (1997) Intensified treatment of stage IV non- small cell lung cancer (NSCLC): Weekly chemotherapy with paclitaxel and carboplatin. Lung Cancer 18(Suppl 1):A122

    Google Scholar 

  53. Georgoulias V, Androulakis N, Dimopoulos C et al: First-line treatment of advanced non-small cell lung cancer with docetaxel and cisplatin: a multicenter phase II study. Ann Oncol 9: 331–334, 1998

    Article  PubMed  CAS  Google Scholar 

  54. Mattson K, Vansteenkiste J, Saarinen A et al (1997) A phase II study of docetaxel (taxotere) alternating with cisplatin with full doses of both drugs for advanced NSCLC. Lung Cancer 18(Suppl 1):A64

    Google Scholar 

  55. Orcel B, Antoine EC, Benhammouda A et al (1997) Interim results of a sequential administration of docetaxel (taxotere) followed by Cisplatin-vindesine in chemotherapy naïve patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). Lung Cancer 18 (Suppl 1):A197

    Google Scholar 

  56. Belani CP, Einzig A, Bonomi P et al (1997) Multi-institutional phase II trial of docetaxel and carboplatin combination in patients with stage IIIB and IV non-small cell lung cancer (NSCLC). Lung Cancer 18(Suppl 1):A52

    Google Scholar 

  57. Capozzoli MJ, Belani CP, Einzig A et al (1998) Multi-institutional phase II trial of docetaxel and carboplatin combination in patients with stage IIIB and IV non-small cell lung cancer. Proc Am Soc Clin Oncol 17:A1845

    Google Scholar 

  58. Peters GJ, Bergman AM, Ruiz van Haoeren VWT et al (1995) Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 22(Suppl 11):72–79

    PubMed  CAS  Google Scholar 

  59. Lopez Cabrerizo MP, Cardenal F, Artal A et al (1997) Gemcitabine plus cisplatin versus etoposide plus cisplatin in advanced non-small cell lung cancer: A randomized trial by the Spanish Lung Cancer Group. Lung Cancer 18(Suppl 1):A27

    Google Scholar 

  60. Sandler A, Nemunaitis J, Dehnam C et al (1998) Phase III study of cisplatin with or without gemcitabine in patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 17:A1747

    Google Scholar 

  61. Crino L, Conte P, De Marinis F et al (1998) A randomized trial of gemcitabine cisplatin versus mitomycin, ifosfamide and cisplatin in advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 17:A1750

    Google Scholar 

  62. Carmichael J, Allerheiligen S, Walling J (1996) A phase I study of gemcitabine and carboplatin in non-small cell lung cancer. Semin Oncol 23(Suppl 10):55–59

    PubMed  CAS  Google Scholar 

  63. Ng EW, Sandler AB, Einhorn LH (1998) A phase II study of carboplatin plus gemcitabine in non-small cell lung cancer. Proc Am Soc Clin Oncol 17:A1801

    Google Scholar 

  64. Rapp E, Pater JL, Willan A et al (1988) Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer-Report of a Canadian multicenter randomized trial. J Clin Oncol 6:633–641

    PubMed  CAS  Google Scholar 

  65. Georgoulias V, Kourousis C, Kakolyris S et al (1997) Second-line treatment of advanced non-small cell lung cancer with paclitaxel and gemcitabine: a preliminary report on an active regimen. Semin Oncol 24(4 Suppl 12):61–66

    CAS  Google Scholar 

  66. Breton JL, Jacoulet P, Pellae-Cosset et al (1997) Phase I study of paclitaxel (P) over 1 hr infusion in combination with vinorelbine (V) in advanced non small cell lung cancer (NSCLC). Lung Cancer 18 (Suppl 1):A202

    Google Scholar 

  67. Chang AY, DeVore R, Gu C et al (1997) Paclitaxel and vinorelbine in non-small cell lung cancer. In vitro and clinical studies. Oncology 11(Suppl 12):31–34

    Google Scholar 

  68. Georgouhas V, Kourousis C, Androulakis N et al (1998) Frontline treatment of advanced non-small cell lung cancer with docetaxel and gemcitabine: A multicenter phase II trial. Proc Am Soc Clin Oncol 17:A1819

    Google Scholar 

  69. Miller VA, Grant SC, Ng K et al (1998) Phase I trial of docetaxel and vinorelbine with filgrastim in patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 17:A1813

    Google Scholar 

  70. Trillet-Lenoir V, Monnier A, Douillard JY et al (1996) Interim results of a phase II study of docetaxel (Taxotere) and vinorelbine in chemotherapy naïve patients with advanced non-small cell lung carcinoma (NSCLC)(abstr 450P). Ann Oncol 7(Suppl 5):95

    Google Scholar 

  71. Kourousis C, Androulakis N, Kakolyris S et al (1996) First line treatment of non- small cell lung carcinoma (NSCLC) with docetaxel and vinorelbine: A phase II study (abstr 1441P). Ann Oncol 7(Suppl 5):93

    Google Scholar 

  72. Lorusso V, Mancarella S, Carpagnano F et al (1998) Gemcitabine plus vinorelbine in patients with stage IIIB-IV non small cell lung cancer. A phase II study. Proc Am Soc Clin Oncol 17:A1808

    Google Scholar 

  73. Esteban E, Llano JLG, Vieitex JM et al (1998) Phase I/II study of gemcitabine plus vinorelbine in non-small cell lung cancer. Proc Am Soc Clin Oncol 17:A1855

    Google Scholar 

  74. Isokangas OP, Mattson K, Joensuu H et al (1998) A phase II study of vinorelbine and gemcitabine in inoperable stage IIIB-IV NSCLC. Proc Am Soc Clin Oncol 17:A1882

    Google Scholar 

  75. Lilenbaum RC, Schwartz MA, Cano R et al (1998) Gemcitabine and navelbine in advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 17:A1901

    Google Scholar 

  76. Kudoh S, Negoro S, Masuda N et al (1997) Phase I/II study of docetaxel and irino- tecan (CPT-11) for previously untreated advanced non-small cell lung cancer (NSCLC). Lung Cancer 18(Suppl 1):A144

    Google Scholar 

  77. Kelly K (1998) The Fox Chase Cancer Center and Free University Investigator’s Workshop and Consensus Conference. St. Thomas, US Virgin Islands, March 26–27

    Google Scholar 

  78. Hainsworth JD, Erland JB, Hon JK et al (1998) Phase I/II trial of paclitaxel (1 hour infusion), carboplatin and gemcitabine in the treatment of advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 17:A1811

    Google Scholar 

  79. Frasci G, Comella P, Panza N et al (1998) Cisplatin-gemcitabine-paclitaxel in advanced non-small cell lung cancer. A dose finding study. Proc Am Soc Clin Oncol 17:A1850

    Google Scholar 

  80. Sorensen JB, Stenbyggard LE, Hansen HH et al (1998) Biweekly paclitaxel, gemcitabine and cisplatin in non-resectable non-small cell lung cancer. Proc Am Soc Clin Oncol 17:A1930

    Google Scholar 

  81. Greco FA (1998) The Fox Chase Cancer Center and Free University Investigator’s Workshop and Consensus Conference. St. Thomas, US Virgin Islands, March 26–27

    Google Scholar 

  82. Comella P, Panza N, Frasci G et al (1997) Gemcitabine (GEM)-cisplatin (CDDP)- vinorelbine (VNR) combination in advanced non-small cell lung cancer (NSCLC). A phase II randomized study. Lung Cancer 18:A231

    Article  Google Scholar 

  83. Gonzalez-Baron M, Garcia MJ, Chacon JI et al (1998) A phase II study of gemcitabine, cisplatin and vinorelbine in patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 17:A1802

    Google Scholar 

  84. Dorta J, Martin G, Constenla M et al (1998) A phase II study of gemcitabine, cisplatin and vinorelbine in patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 17:A1853

    Google Scholar 

  85. Viallet J, Laberge F, Martins H et al (1996) A phase II trial of docetaxel alternating with cisplatin and vinorelbine in non small cell lung cancer. Ann Oncol 7(Suppl 5):A440P

    Google Scholar 

  86. Georgoulias V, Kourousis C, Androulakis N et al (1997) Docetaxel(Taxotere) and vinorelbine in the treatment of non-small cell lung cancer. Semin Oncol 24 (Suppl 14):9–14

    CAS  Google Scholar 

  87. Masters G, Mauer AM, Hoffman PC et al: A phase I-II study of paclitaxel, ifosfa- mide, and vinorelbine with filgrastim (rhG-CSF) support in advanced non-small cell lung cancer. Ann Oncol 9: 677–680, 1998

    Article  PubMed  CAS  Google Scholar 

  88. Castellano D, Lianes P, Calzas J et al (1998) Non-cisplatin based chemotherapy for advanced non small cell lung cancer: A phase II study with gemcitabine, ifosfamide and vinorelbine. Proc Am Soc Clin Oncol 17:A1847

    Google Scholar 

  89. Comella P, Frasci G, DeCataldis G et al: Cistaplin/carboplatin + etoposide + vnorel- bine in advanced NSCLC. A randomised phase IL Gruppo Oncologico Compano. Br J Cancer 74: 1805–1811, 1998

    Article  Google Scholar 

  90. Zarogoulidis K, Papagiannis A, Constantinidis TC et al (1997) Paclitaxel, carboplatin and mitomycin as first line treatment in patients with advanced non-small cell lung cancer (NSCLC). Lung Cancer 18(Suppl 1):A227

    Google Scholar 

  91. Zaniboni A, Meriggi F, Rizzi A et al (1997) Paclitaxel, ifosfamide and carboplatin for the treatment of stages IIIB and IV non-small cell lung cancer: Preliminary results. Semin Oncol 24(Suppl 12):70–72

    CAS  Google Scholar 

  92. Donnellan P, Duffy K, Murray R et al (1997) Combination of docetaxel (Taxotere), ifosfamide and cisplatin in non-small cell lung cancer (NSCLC). Lung Cancer 18 (Suppl 1): A228

    Google Scholar 

  93. Perol M, Guerin JC, Thomas P et al (1996) Multicenter randomized trial comparing cisplatin-mitomycin-vinorelbine versus cisplatin-mitomycin-vindesine in advanced non-small cell lung cancer. ’Groupe Francais de Pneumo-cancerologie’ Lung Cancer 14:119–134

    Article  CAS  Google Scholar 

  94. Mohedano N, Sanchez-Rovira P, Medina B et al (1997) Phase II trial of gemcitab- ine in combination with cisplatin and ifosfamide in advanced non-small cell lung cancer (NSCLC). Lung Cancer 18(Suppl 1):A159

    Google Scholar 

  95. Bameto IC, De la Haba J, Gosalbez B et al (1997) Phase II activity of cisplatin (CDDP) plus ifosfamide (IFO) and gemcitabine (GEM) in non small cell lung cancer (NSCLC). Preliminary results. Lung Cancer 18 (Suppl 1):A204

    Google Scholar 

  96. Jaakkimainen L, Goodwin PJ, Pater J et al (1990) Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer. J Clin Oncol 8:1301–1309

    PubMed  CAS  Google Scholar 

  97. Evans WK (1997) Treatment of NSCLC with chemotherapy is controversial because of low response and high cost. Lung Cancer 18(Suppl2): 117–118

    Article  Google Scholar 

  98. Pritchard RS, Anthony SP (1996) Chemotherapy plus Radiotherapy Compared with Radiotherapy Alone in the Treatment of Locally Advanced, Unresectable, NSCLC. A meta-analysis. Ann Int Med 125:723–729

    PubMed  CAS  Google Scholar 

  99. Dillman RO, Seagren SL, Hemdon J et al (1990) A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small cell lung cancer. N Engl J Med 323:940–945

    Article  PubMed  CAS  Google Scholar 

  100. Dillman RO, Hemdin J, Seagren SL et al (1996) Improved survival in stage III non- small cell lung cancer: seven year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 88:1210–1215

    Article  PubMed  CAS  Google Scholar 

  101. Sause WT, Kolesar P, Taylor S et al (1998) Five-year results; Phase III trial of regionally advanced unresectable non-small cell lung cancer, RTOG 8808, ECOG 4588, SWOG 8992. Proc Am Soc Clin Oncol 17:A1743

    Google Scholar 

  102. Le Chevalier T, Arriagada R, Quiox E et al (1991) Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small cell lung cancer: First analysis of a randomized trial in 353 patients. J Natl Cancer Inst 83:417–423

    Article  PubMed  Google Scholar 

  103. Schaake-Koning C, Van Den Bogert W, Dalesio O et al (1992) Effects of concomitant cisplatin and radiotherapy in inoperable non-small cell lung cancer. N Engl J Med 326:524–530

    Article  PubMed  CAS  Google Scholar 

  104. Jeremic B, Shibamoto Y, Acinovic L et al (1995) Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small cell lung cancer. J Clin Oncol 13:452–458

    PubMed  CAS  Google Scholar 

  105. Jeremic B, Shibamoto Y, Acinovic L et al (1996) Hyperfractionated radiation therapy with or without concurrent low dose daily carboplatin/etoposide for stage III non-small cell lung cancer: A randomized study. J Clin Oncol 14:1065–1070

    PubMed  CAS  Google Scholar 

  106. Takada Y, Furuse K, Fukuoka YH et al (1997) A randomized phase III study of concurrent versus sequential thoracic radiotherapy (TRT) in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer (NSCLC). Lung Cancer 18(Suppl 1):A294

    Google Scholar 

  107. Leonard C, Chan DC, Chou PC et al (1996) Paclitaxel enhances in vitro radiosen- sitivity of squamous carcinoma cell lines of the head and neck. Cancer Res 56:5198–5204

    PubMed  CAS  Google Scholar 

  108. McGinn CJ, Shewach DS, Lawrence TS (1996) Radiosensitizing nucleosides. J Natl Cancer Inst 88:1193–1203

    Article  PubMed  CAS  Google Scholar 

  109. Okishio K, Kudoh S, Kurihara N et al (1996) Irinotecan (CPT-11) enhances the radiosensitivity of lung cancer cells in vitro. Cellular Pharmacol 3:247–252

    CAS  Google Scholar 

  110. Langer CJ, Movsas B, Hudes R et al (1997) Induction Paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma: Report of Fox Chase Cancer Center Study 94–001. Semin Oncol 24(Suppl 12):89–95

    CAS  Google Scholar 

  111. Isokangas OP, Joensuu H, Halme M et al: Paclitaxel (Taxol) and carboplatin followed by concomitant paclitaxel, cisplatin and radiotherapy for inoperable stage III NSCLC. Lung Cancer 20: 127–123, 1998

    Article  PubMed  CAS  Google Scholar 

  112. Greco FA, Stroup SL, Gray JR et al (1996) Paclitaxel in combination with radiotherapy in patients with unresectable stage III non-small cell lung cancer. J Clin Oncol 14:1642–1648

    PubMed  CAS  Google Scholar 

  113. Choy H, Safran H, Akerley W et al: Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer. Clin Cancer Res 4: 1931–1936, 1998

    PubMed  CAS  Google Scholar 

  114. Choy H, Ackerley W, Safran H et al: Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small cell lung cancer. J Clin Oncol 16: 3316–3322, 1998

    PubMed  CAS  Google Scholar 

  115. Belani CP, Aisner J, Day R et al (1997) Promising long term outcome of weekly paclitaxel and carboplatin with simultaneous thoracic radiotherapy (TRT) for locally advanced non-small cell lung cancer (NSCLC). Lung Cancer 18(Suppl 1):A242

    Google Scholar 

  116. Choy H, DeVore RF, Hande KR et al: Preliminary analysis of a phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small cell lung cancer. Semin Oncol 24 (suppl 12): 21–26, 1997

    CAS  Google Scholar 

  117. Comella G, Frasci G, Scoppa G et al (1997) Weekly paclitaxel/cisplatin with concurrent radiotherapy in patients with locally advanced non-small cell lung cancer: A phase I study. Semin Oncol 24(Suppl 12):113–116

    CAS  Google Scholar 

  118. Lau D, Ryu J, Gandara D et al (1997) Twice-weekly paclitaxel and radiation for stage III non-small cell lung cancer. Semin Oncol 24(Suppl 12): 102–109

    Google Scholar 

  119. Pisch J, Pagluica T, Malamud S et al (1997) Uninterrupted twice a day irradiation with concomitant chemotherapy and G-CSF for advanced lung cancer. Phase I-II study. Lung Cancer 18(Suppl 1):A262

    Google Scholar 

  120. Rigas J, Leopold K, Maurer LH et al (1997) Daily pachtaxel and thoracic radiation for the treatment of stage II–IIIB NSCLC. Lung Cancer 18(Suppl 1):A268

    Google Scholar 

  121. Koukourakis MI, Kourousis C, Kamilaki M et al: Weekly docetaxel and concomitant boost radiotherapy for non-small cell lung cancer. A phase I/II dose escalation trial. Eur J Cancer 34(6): 838–844, 1998

    Article  PubMed  CAS  Google Scholar 

  122. Gregor A (1997) Gemcitabine plus radiotherapy for non-small cell lung cancer. Semin Oncol 24(8)39–41

    CAS  Google Scholar 

  123. Lawrence T, Eisbruch A and Shewach DS: Gemcitabine-mediated radiosensitiza- tion. Semin Oncol 24 (2 suppl 7): 24–28, 1997

    CAS  Google Scholar 

  124. Scalliet P, Goor C, Galdermans D et al (1998) Gemzar (gemcitabine) with thoracic radiotherapy. A phase II pilot study in chemonaive patients with advanced non- small cell lung cancer. Proc Am Soc Clin Oncol 17:A1923

    Google Scholar 

  125. Masters G, Haraf DJ, Hoffman PC et al: Phase I study of vinorelbine, cisplatin, and concomitant thoracic radiation in the treatment of advanced chest malignancies. J Clin Oncol 16(6): 2157–2163, 1998

    PubMed  CAS  Google Scholar 

  126. Viallet J, Rousseau P, Souhami L et al (1995) A phase I/II trial of neoadjuvant chemotherapy with cisplatin and vinorelbine (Navelbine) followed by accelerated thoracic irradiation in inoperable non-small cell lung cancer. Proc Am Soc Clin Oncol 14:A1169

    Google Scholar 

  127. Zatloukal P, Petmzelka L, Zemanova M et al (1998) Vinorelbine plus cisplatin and concurrent radiotherapy in advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 17:A1947

    Google Scholar 

  128. Nakagawa K, Yamamoto, Kudoh S et al (1998) Irinotecan (CPT-11) and carboplatin with concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer. Preliminary results. Proc Am Soc Clin Oncol 17:A1909

    Google Scholar 

  129. Vokes EE, Leopold KA, Hemdon JE et al (1997) A CALGB randomized phase II study of gemcitabine or paclitaxel or vinorelbine with cisplatin as induction chemotherapy (Inc CT) and concomitant chemoradiotherapy (XRT) in stage HIB non- small cell lung cancer (NSCLC): feasibility data (CALGB #9431). Proc Am Soc Clin Oncol 16:A1636

    Google Scholar 

  130. Bunn PA Jr (1994) The Treatment of Non-Small Cell Lung Cancer: Current Perspectives and Controversies, Future Directions. Semin Oncol 21(Suppl 6):49–59

    PubMed  Google Scholar 

  131. Martini N, Kris M, Flehinger B et al (1993) Preoperative chemotherapy for stage IIIA (N2) lung cancer: The Sloan Kettering experience with 136 patients. Ann Thorac Surg 55:1365–1374

    Article  PubMed  CAS  Google Scholar 

  132. Burkes R, Ginsberg, Shepherd F et al (1992) Induction chemotherapy with mitomycin C, vindesine and cisplatin for stage III unresectable non-small cell lung cancer: results of the Toronto phase II trial. J Clin Oncol 10:580–586

    PubMed  CAS  Google Scholar 

  133. Sugarbaker DJ, Hemdon J, Kohman LJ et al (1995) Results of Cancer and Leukemia Group B Protocol 8935: multiinstitutional phase II trimodality trial for stage IIIA (N2) NSCLC. J Thorac Cardiovasc Surg 109:473–485

    Article  PubMed  CAS  Google Scholar 

  134. Rosell R, Gomez-Codina J, Camps C et al (1994) A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non- small cell lung cancer. N Engl J Med 330:153–158

    Article  PubMed  CAS  Google Scholar 

  135. Roth JAB, Fossella F, Komaki R et al (1992) A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non- small cell lung cancer. J Natl Cancer Inst 86:673–680

    Article  Google Scholar 

  136. Albain KS, Rusch V, Crowley J et al (1995) Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA and IIIB non-small cell lung cancer: Mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 13:1880–1892

    PubMed  CAS  Google Scholar 

  137. Eberhardt W, Wilke H, Stamatis G et al (1998) Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small cell lung cancer: Mature resuhs of a phase II trial. J Clin Oncol 16:622–634

    PubMed  CAS  Google Scholar 

  138. Ukena D, Leutz M, Huwer H et al (1997) Induction chemotherapy with paclitaxel and carboplatin in locally advanced stage IIIA/IIIB non-small cell lung cancer (NSCLC). Lung Cancer 18(Suppl 1):A230

    Google Scholar 

  139. Friedland D, Greenberg R, Miller W et al (1997) Phase II trial of perioperative paclitaxel plus granulocyte-colony stimulating factor in mediastinoscopy staged IIIA-N2 non-small cell lung cancer. Lung Cancer 18(Suppl 1):A283

    Google Scholar 

  140. O’Rourke MA, Klassy JA, Denham CA et al (1997) An evaluation of a two drug combination of navelbine and cisplatin as neoadjuvant therapy for patients presenting with inoperable stage IIIA or IIIB non-small cell lung cancer. Proc Am Soc Clin Oncol 16:A1717

    Google Scholar 

  141. Bardet E, Douillard JY, Riviere A et al (1997) Induction chemotherapy (ICT cisplatin and vinorelbine) followed by a combination of daily irradiation and carbo- platine (CBDCA) in stage IIIB non-small cell lung cancer (NSCLC): Final analysis of a phase II trial. Lung Cancer 18(Suppl 1):A352

    Google Scholar 

  142. Splinter TAW, Kirkpatrick A, van Meerbeeck J et al (1998) Randomized trial of surgery versus radiotherapy in patients with stage IIIA non-small cell lung cancer after a response to induction chemotherapy. Intergroup study 08941. Proc Am Soc Clin Oncol 17:A1742

    Google Scholar 

  143. Wagner H Jr, Lad T, Piantadosi S (1991) Randomized phase II evaluation of preoperative radiation therapy and preoperative chemotherapy with mitomycin C, vinblastine and cisplatin in patients with technically unresectable IIIA and IIIB non- small cell lung Cancer. Lung cancer 7:157

    Article  Google Scholar 

  144. Weisenburger JH, Lung Cancer Study Group (1986) Effects of postoperative mediastinal radiation on completely resected stage II and stage III epidermoid carcinoma of the lung. N Engl J Med 315:1377

    Article  Google Scholar 

  145. Stewart LA, Burdett S, Souhami RL (1998) Post operative radiotherapy (PORT) in non-small cell lung cancer: A meta-analysis using individual patient data from randomised clinical trials. Proc Am Soc Clin Oncol 17: A1760

    Google Scholar 

  146. Crook A, Duffy A, Girling DJ et al (1997) Survey on the treatment of non-small cell lung cancer in England and Wales. Lung Cancer 18(Suppl 1):9

    Article  Google Scholar 

  147. Yellan SB, Cella DP (1995) Someone to live for: Social well being, parenthood states, and decision making in oncology. J Clin Oncol 13:1255–1264

    Google Scholar 

  148. Slevin ML, Stubbs L, Plant HJ et al (1990) Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses and general public. BMJ 2/300(6737): 1458–1460

    Article  Google Scholar 

  149. Pisters KMW, Ginsberg RJ (1998) Phase II trial of induction paclitaxel & carboplatin in early stage (T2N0, T1–2N1, & selected T3N0–1) non-small cell lung cancer. Proc Am Soc Clin Oncol 17:A1738

    Google Scholar 

Download references

Authors
  1. A. F. Soriano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. A. Bunn Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. MD Anderson Cencer Center, Cepartment of Breast Medical Oncology, University of Texas, 1515 Holcombe Boulevard, 77030, Houston, Texas, USA

    Gabriel N. Hortobagyi

  2. Pitié-Salpétrière Hospital, SOMPS, 47, bd de l’Hôpital, 75651, Paris Cedex 13, France

    David Khayat

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer-Verlag France

About this paper

Cite this paper

Soriano, A.F., Bunn, P.A. (1999). New Drug Combinations in NSCLC: Progress in Cancer Therapy. In: Hortobagyi, G.N., Khayat, D. (eds) Progress in Anti-Cancer Chemotherapy. Progress in Anti-Cancer Chemotherapy, vol 3. Springer, Paris. https://doi.org/10.1007/978-2-8178-0918-2_8

Download citation

  • DOI: https://doi.org/10.1007/978-2-8178-0918-2_8

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-59666-7

  • Online ISBN: 978-2-8178-0918-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation